Get started
Author

Diane J. Post

Observed names: DIANE POST, Diane J. Post, Diane J Post, Diane Post, Diane J. Post
ORCID: 0000-0003-3890-9116
Observed ORCID: 0000-0003-3890-9116
OpenAlex ID: A5071885123
A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases
2018 · Emily J Erbelding, Diane J Post, et al. · The Journal of Infectious Diseases · 440
PDF
Defining the risk of SARS-CoV-2 variants on immune protection
2022 · Marciela M. DeGrace, Elodie Ghedin, et al. · Nature · 171
PDF
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
2022 · Kirsten E. Lyke, Robert L. Atmar, et al. · Cell Reports Medicine · 153
A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future
2021 · Kristine A. Moore, Julia T. Ostrowsky, et al. · Vaccine · 75
PDF
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023 · Angela R. Branche, Nadine G. Rouphael, et al. · Nature Medicine · 61
PDF
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
2023 · Kirsten E. Lyke, Robert L. Atmar, et al. · npj Vaccines · 33
PDF
Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant
2022 · Kirsten E. Lyke, Robert L. Atmar, et al. · SSRN Electronic Journal · 31
Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity
2019 · Bruce L. Innis, Francesco Berlanda Scorza, et al. · Vaccine · 25
PDF
Regulation and Characterization of the Interferon-α Present in Patients with Advanced Human Immunodeficiency Virus Type 1 Disease
1996 · SUSAN SWINDELLS, TONIA BALDWIN, et al. · Journal of Interferon & Cytokine Research · 16
Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations
2019 · Bruce L. Innis, Francesco Berlanda Scorza, et al. · Vaccine · 14
PDF
Meeting Report From “Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID‐19 Pandemic”
2024 · Florian Krammer, Jacqueline M. Katz, et al. · Influenza and Other Respiratory Viruses · 10
PDF
SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
2022 · Kirsten E. Lyke, Robert L. Atmar, et al. · medRxiv · 5
PDF
Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation
2024 · M. Chelsea Lane, Catherine J. Luke, et al. · Influenza and Other Respiratory Viruses · 4
PDF
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
2023 · Nadine G Rouphael, Angela R Branche, et al. · The Journal of Infectious Diseases · 3
PDF
US National Institutes of Health Prioritization of SARS-CoV-2 Variants
2023 · Sam Turner, Arghavan Alisoltani, et al. · Emerging infectious diseases · 3
Collaborative influenza vaccine innovation centers (CIVICs) program
2025 · Kentner L. Singleton, Diane J. Post, et al. · Vaccine · 2
PDF
Workshop report: Optimization of animal models to better predict influenza vaccine efficacy
2020 · M. Chelsea Lane, Jennifer L. Gordon, et al. · Vaccine · 2
The Landscape of Observational COVID-19 Cohort Studies Funded by the National Institute of Allergy and Infectious Diseases
2023 · Reed S Shabman, Mason Booth, et al. · American Journal of Epidemiology · 1
PDF
Author response for "Meeting Report From “Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID‐19 Pandemic”"
2024 · Florian Krammer, Jacqueline M. Katz, et al.
Works count: 19
Citation count: 1,049
H-index: 10
I10-index: 11
Year
Topic
Type